중추신경계 바이오마커 시장 규모, 점유율, 성장 분석 : 유형별, 용도별, 최종 사용자별, 지역별 - 업계 예측(2026-2033년)

Global Central Nervous System Biomarkers Market size was valued at USD 6.05 Billion in 2024 and is poised to grow from USD 6.54 Billion in 2025 to USD 12.2 Billion by 2033, growing at a CAGR of 8.1% during the forecast period (2026-2033).

The global market for CNS biomarkers is witnessing substantial growth, fueled by the rising incidence of neurological disorders, influenced by demographic shifts and lifestyle changes. This surge in prevalence prompts a heightened demand for precision in early diagnosis, fostering the use of biomarker-based diagnostic technologies. Innovations in research are enhancing our comprehension of the molecular and genetic underpinnings of CNS conditions, leading to the emergence of novel biomarkers that improve sensitivity and specificity. Furthermore, the shift towards personalized medicine necessitates biomarker analysis for optimized patient selection and treatment monitoring. Despite challenges such as the need for standardization, regulatory hurdles, and the intrinsic complexity of CNS disorders, CNS biomarkers remain pivotal in advancing therapeutic strategies and drug development in neuroscience.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Central Nervous System Biomarkers market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Central Nervous System Biomarkers Market Segments Analysis

Global Central Nervous System Biomarkers Market is segmented by Type, Application, End-User and region. Based on Type, the market is segmented into Safety Biomarkers, Efficacy Biomarkers and Validation Biomarkers. Based on Application, the market is segmented into Diagnostics, Drug Discovery & Development and Personalized Medicine. Based on End-User, the market is segmented into Hospitals, Diagnostic Laboratories, Research Institutes and Biopharmaceutical Companies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Central Nervous System Biomarkers Market

The increasing incidence of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis, significantly propels the growth of the Central Nervous System (CNS) biomarkers market. As these conditions become more widespread, the urgent need for precise and timely diagnoses intensifies, driving healthcare providers and researchers to seek innovative biomarker-based diagnostic solutions. This heightened focus on early detection and effective management of neurological diseases fosters a growing demand for advanced biomarkers, ultimately shaping the landscape of the CNS diagnostics market. Moreover, the quest for improved patient outcomes further amplifies the reliance on these critical diagnostic tools.

Restraints in the Global Central Nervous System Biomarkers Market

The Global Central Nervous System Biomarkers market faces significant challenges due to the intricate and multifaceted nature of CNS disorders. This complexity makes it difficult to pinpoint reliable and specific biomarkers that truly represent the underlying disease mechanisms. Furthermore, the variability among different CNS conditions complicates the development of universal biomarkers, as they may not uniformly correlate with the diverse clinical manifestations and pathological processes of these disorders. As a result, the quest for accurate biomarkers that can effectively guide diagnosis and treatment remains a significant obstacle within this market, hindering progress and innovation.

Market Trends of the Global Central Nervous System Biomarkers Market

The Global Central Nervous System Biomarkers market is experiencing a transformative evolution driven by significant technological advancements. Innovations like high-throughput screening techniques, next-generation sequencing, and sophisticated imaging modalities are enhancing the sensitivity and specificity of biomarker detection. This surge in technology not only improves the accuracy of diagnosing and monitoring central nervous system disorders but also facilitates personalized medicine approaches. As a result, the demand for reliable and precise biomarkers is rising, attracting investment and fostering collaborations among biotech firms, research institutions, and healthcare providers, ultimately propelling growth in this dynamic market.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Central Nervous System Biomarkers Market Size by Type & CAGR (2026-2033)

• Market Overview
• Safety Biomarkers
• Efficacy Biomarkers
• Validation Biomarkers

Global Central Nervous System Biomarkers Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diagnostics
  • Alzheimer's Disease
  • Parkinson's Disease
  • Multiple Sclerosis
  • Stroke
• Drug Discovery & Development
  • Preclinical Studies
  • Clinical Trials
• Personalized Medicine
  • Genomic Biomarkers
  • Proteomic Biomarkers
  • Metabolomic Biomarkers

Global Central Nervous System Biomarkers Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Biopharmaceutical Companies

Global Central Nervous System Biomarkers Market Size & CAGR (2026-2033)

• North America (Type, Application, End-User)
  • US
  • Canada
• Europe (Type, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PerkinElmer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axon Neuroscience SE (Slovakia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alector Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Oryzon Genomics S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Banyan Biomarkers Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Avacta Group PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Geno Technology Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alseres Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aposense Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations